EN DE
Watch GeneReach Biotechnology for free: we tell you when fair value or trend changes.
Data-driven stock valuation

GeneReach Biotechnology (4171) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of GeneReach Biotechnology stock TWD 3.34, price TWD 15.00, that is 77.7% below the price, quality 49 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0004171004

GB GeneReach Biotechnology logo Thin data Nov 4, 2026

GeneReach Biotechnology

4171 · TWO
Very expensive, weak quality

Our calculation puts a fair price 78% below what the stock costs today.

Low debt
Ranks above peers (7/11)
Quality 49/100
Profit last quarter 66% below a year ago.
Fair value 3.34 TWD · Strongly overvalued
Weak Growth (revenue 5y −22.9 %/yr in TWD)
Loss-making · -18.1% net margin (TTM)
Negative free cash flow
Narrow moat 8/100 · thin data
Thin data
Watch GeneReach Biotechnology for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

112.58 TWD 15.00 TWD Fair Value 3.34 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range 15.00 TWD – 112.58 TWD · fair‑value band 2.20 TWD – 4.17 TWD · the 15.00 TWD price screens above the 3.34 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow GeneReach Biotechnology in your weekly email

Every Wednesday you see whether GeneReach Biotechnology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan.

Show moreShow less

The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assays, iiPCR Specific Reagents, research reagents and consumables, as well as taco Nucleic Acid Extraction Reagents, IQ REAL Quantitative System, and IQ2000 Detection & Prevention System.

It also provides training program; and other services comprising molecular diagnostic technical solutions and laboratory installation, OEM/ODM contract manufacturing, and research collaborations services. The company was founded in 2004 and is headquartered in Taichung, Taiwan.

Stock analysis

GeneReach Biotechnology (4171) currently trades at 15.00 TWD, while our model-based Fair Value estimate is 3.34 TWD, 78% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 93/100, which puts the data coverage at low.

Scenario range: 2.20 TWD (bear) to 4.17 TWD (bull), the price of 15.00 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

GeneReach Biotechnology reported revenue of 233M TWD in FY2025 versus 1.0B TWD in FY2021, a compound −30.8%/yr. Reported net income was −110M TWD in FY2025.

Key figures

Market cap 869M TWD (≈ $26.5M) Micro · P/S ratio 3.98 · EPS (TTM) −0.7600 TWD · Dividend yield 1.7% · Net margin −18.1% · Return on equity −7.6% · Return on assets (EBIT) 1.4% (5-year average) · Operating margin −14.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 34% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −78%, 4171 screens richer than that median.

Fair Value models

Bear 2.20 TWD Fair Value 3.34 TWD Bull 4.17 TWD
Price 15.00 TWD · Downside -77.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 2.20 TWD 3.34 TWD 4.17 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) 2.20 TWD 3.34 TWD 4.17 TWD 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 9
How much profit the company makes from its sales and capital
Quality Growth 68
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 74
Debt, balance sheet and risk of trouble
Investment 94
Does it invest with discipline instead of growing at any price?
Low Volatility 69
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 89
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+12.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−32.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.9%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
40.2% (2020) → −37.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

4171 screens overvalued: fair value 78% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare GeneReach Biotechnology with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 49 · Above median
Fair Value upside −77.7% · Bottom 25%
Profitability
Return on assets −12.5% · Below median
Net margin (12 months) −18.1% · Below median
Operating margin (12 months) −14.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 10.1% · Above median
Dividend yield (12 months) 1.7% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.48× · Cheaper than median
P/S (12 months) 3.65× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)51 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)34 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 4171
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 4171
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 4171
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 4171
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 4171
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 4171
argenx SE ARGX $927.21 $908.40 −2% vs 4171
CSL Limited CSL A$200.77 A$183.04 −9% vs 4171
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 4171
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 4171

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

GeneReach Biotechnology: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "GeneReach Biotechnology Fair Value". https://www.fairvalue-calculator.com/stock/4171

Frequently asked questions

Is GeneReach Biotechnology (4171) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 3.34 TWD versus a price of 15.00 TWD, about 78% lower (overvalued).
What is the fair value of 4171?
Our model-based fair value for GeneReach Biotechnology is 3.34 TWD (as of Nov 4, 2026), built from audited fundamentals. The current price: 15.00 TWD.
What is the quality score of 4171?
GeneReach Biotechnology has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GeneReach Biotechnology (4171)?
Our model-based price target is the fair value of 3.34 TWD (as of Nov 4, 2026) from 1 valuation models. Cautious scenario 2.20 TWD, optimistic scenario 4.17 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the GeneReach Biotechnology stock forecast for 2026?
Our models put fair value at 3.34 TWD, about 78% lower versus a price of 15.00 TWD (overvalued). Cautious scenario 2.20 TWD, optimistic scenario 4.17 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of GeneReach Biotechnology (4171)?
GeneReach Biotechnology reported trailing-twelve-month revenue of about 238M TWD (latest available figure, as of Nov 4, 2026).
Does GeneReach Biotechnology pay a dividend?
GeneReach Biotechnology currently shows a dividend yield of 1.69% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of GeneReach Biotechnology (4171)?
GeneReach Biotechnology has a dividend yield of 1.7%.
What is the intrinsic value of GeneReach Biotechnology (4171)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GeneReach Biotechnology it is 3.34 TWD per share (as of Nov 4, 2026), against a price of 15.00 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is GeneReach Biotechnology stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 4171 trades above its calculated fair value: price 15.00 TWD, fair value 3.34 TWD, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4171?
No. The price is what the market pays today (15.00 TWD); the fair value is what the company's own numbers justify (3.34 TWD). For GeneReach Biotechnology the two are 11.66 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is GeneReach Biotechnology worth?
The market values GeneReach Biotechnology at about 869M TWD (market capitalisation, as of Nov 4, 2026). Per share that is 15.00 TWD; our models calculate a fair value of 3.34 TWD per share.
What do the bullish and bearish scenarios say about 4171?
Our models span a range for GeneReach Biotechnology: cautious scenario 2.20 TWD, base 3.34 TWD, optimistic 4.17 TWD per share (as of Nov 4, 2026, price 15.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of GeneReach Biotechnology (4171)?
Balance-sheet figures for GeneReach Biotechnology (as of Nov 4, 2026): return on equity −7.6%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 4171 from its 52-week high?
GeneReach Biotechnology trades at 15.00 TWD, about 34% below its 52-week high of 22.85 TWD and at the low of 15.00 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 3.34 TWD is for.
Which stocks are comparable to GeneReach Biotechnology?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GeneReach Biotechnology stock attractive at the current price?
The data as of Nov 4, 2026: price 15.00 TWD, calculated fair value 3.34 TWD (−78%), Quality Score 49/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4171 calculated?
We run GeneReach Biotechnology through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 3.34 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. GeneReach Biotechnology itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GeneReach Biotechnology (4171)?
The closing price on Nov 6, 2026 was 15.00 TWD. Our model-based fair value is 3.34 TWD, about 78% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GeneReach Biotechnology right now?
The price sits above even our optimistic bull case (4.17 TWD). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (2.20 TWD to 4.17 TWD) leaves room in how you read the outcome.

Key figures of GeneReach Biotechnology

How large is the market capitalisation of GeneReach Biotechnology (4171)?
The market capitalisation of GeneReach Biotechnology is 869M TWD (≈ $26.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GeneReach Biotechnology (4171)?
The price-to-sales ratio of GeneReach Biotechnology is 3.98 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GeneReach Biotechnology (4171)?
Earnings per share at GeneReach Biotechnology are −0.7600 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of GeneReach Biotechnology (4171)?
The dividend yield of GeneReach Biotechnology is 1.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of GeneReach Biotechnology (4171)?
The net margin of GeneReach Biotechnology is −18.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GeneReach Biotechnology (4171)?
The return on equity (ROE) of GeneReach Biotechnology is −7.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GeneReach Biotechnology (4171)?
On an EBIT basis the return on assets of GeneReach Biotechnology is 1.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GeneReach Biotechnology (4171)?
The operating margin of GeneReach Biotechnology is −14.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GeneReach Biotechnology (4171)?
Revenue at GeneReach Biotechnology is growing +10.1% versus a year earlier (3y avg −32.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at GeneReach Biotechnology (4171)?
Earnings per share at GeneReach Biotechnology are growing −65.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does GeneReach Biotechnology (4171) generate?
The free cash flow of GeneReach Biotechnology is −25.2M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does GeneReach Biotechnology (4171) carry?
The net debt of GeneReach Biotechnology is 66.5M TWD (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch GeneReach Biotechnology in the live analysis

One click puts GeneReach Biotechnology on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.